Conclusions

In the SENSCIS trial, progression of SSc-ILD over 52 weeks was observed in patients with a time since onset of first non-Raynaud symptom of more than 3 years, as well as in patients with a shorter disease duration. The effect of nintedanib on reducing the rate of decline in FVC in patients with SSc-ILD was consistent across subgroups with differing times since onset of first non-Raynaud symptom.